Bladder CancerPhase 3NCT00014534
Combination Chemotherapy in Treating Patients With Bladder Cancer
A Phase 3 study testing filgrastim, cisplatin and doxorubicin hydrochloride in people with Bladder Cancer, run by Alliance for Clinical Trials in Oncology at 285 sites in United States.
Trial summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Bladder Cancer
- What is being tested?
- filgrastim, cisplatin and doxorubicin hydrochloride
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 42 participants
- Where
- 285 sitesUnited States
- Study dates
- Mar 2004to Apr 2009
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
DISEASE CHARACTERISTICS:
- Histologically confirmed transitional cell carcinoma of the bladder
- Any T, N+, M0 OR
- T3a-4a, N0, M0
- At least 6 weeks but no more than 3 months since prior complete resection of bladder
- Cystoprostatectomy plus pelvic lymph node dissection in males
- Cystectomy/total abdominal hysterectomy/bilateral salpingo-oophorectomy plus pelvic lymph node dissection in females
- Negative surgical margins
- Carcinoma in situ allowed
- No partial cystectomy or transurethral bladder tumor resection as definitive loco-regional therapy
- Prostate cancer detected in resected specimen allowed if post-operative PSA is no more than 0.05 mg/dL
- No metastatic or recurrent disease by post-operative chest x-ray and CT scan of abdomen and pelvis
PATIENT CHARACTERISTICS:
Age:
- 18 and over
Performance status:
- ECOG 0-1
Hematopoietic:
- Absolute neutrophil count ≥ 1,500/mm^3
- Platelet count ≥ 150,000/mm^3
Hepatic:
- Bilirubin ≤ 1.5 times upper limit of normal (ULN)
- Alkaline phosphatase ≤ 2 times ULN
- AST ≤ 2 times ULN
Renal:
- Creatinine ≤ 1.5 mg/dL OR
- Creatinine clearance ≥ 60 mL/min
Cardiovascular:
- Normal cardiac function by history, physical exam, or chest radiograph
- Left ventricular ejection fraction at least 50% by radionuclide ventriculogram or echocardiogram, for prior cardiac disease
- No New York Heart Association class III or IV heart disease
- No serious cardiac arrhythmias including first-, second-, and third-degree heart block
Other:
- Negative pregnancy test
- No uncontrolled infection
- No other active cancer within the past 5 years except non-melanoma skin cancer or curatively treated carcinoma in situ of the cervix
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- Not specified
Chemotherapy:
- No prior systemic chemotherapy
Endocrine therapy:
- Not specified
Radiotherapy:
- No prior radiotherapy to bladder
Trial locations and contacts
285 sites in 1 country.
285 sites in 1 country
United States285 sites
Akron City Hospital at Summa Health System
Akron, Ohio, 44304
Phoebe Cancer Center at Phoebe Putney Memorial Hospital
Albany, Georgia, 31703
Emory University Hospital - Atlanta
Altanta, Georgia, 30322
McFarland Clinic, P.C.
Ames, Iowa, 50010
Rose Ramer Cancer Clinic at Anderson Area Medical Center
Anderson, South Carolina, 29621
CCOP - Michigan Cancer Research Consortium
Ann Arbor, Michigan, 48100
Fox Valley Hematology and Oncology
Appleton, Wisconsin, 54911-3496
Arroyo Grande Community Hospital
Arroyo Grande, California, 93420
Randolph Hospital
Asheboro, North Carolina, 27203
Hematology and Oncology of Northeast Georgia
Athens, Georgia, 30607
MBCCOP-Medical College of Georgia Cancer Center
Augusta, Georgia, 30912
Aurora Presbyterian Hospital
Aurora, Colorado, 80012
Rush-Copley Cancer Care Center
Aurora, Illinois, 60507
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, 21287-8936
St. Francis Hospital and Health Centers
Beech Grove, Indiana, 46107
CCOP - Montana Cancer Consortium
Billings, Montana, 59101
Deaconess Billings Clinic - Downtown
Billings, Montana, 59101
Northern Rockies Radiation Oncology Center
Billings, Montana, 59101
St. Vincent Healthcare
Billings, Montana, 59101
Deaconess Billings Clinic Cancer Center
Billings, Montana, 59107
Bismarck Cancer Center
Bismarck, North Dakota, 58501
Medcenter One Health System
Bismarck, North Dakota, 58501
Mid Dakota Clinic, P.C.
Bismarck, North Dakota, 58501
St. Alexius Medical Center
Bismarck, North Dakota, 58501
St. Joseph Medical Center
Bloomington, Illinois, 61701
St. Elizabeth Boardman Cancer Center
Boardman, Ohio, 44512
Lynn Regional Cancer Center of Boca Raton Community Hospital
Boca Raton, Florida, 33486
Boulder Community Hospital
Boulder, Colorado, 80301
Bozeman Deaconess Hospital
Bozeman, Montana, 59715
Roswell Park Cancer Institute
Buffalo, New York, 14263
Fairview Ridges Hospital
Burnsville, Minnesota, 55337
St. James Community Hospital
Butte, Montana, 59701
Cancer Institute of New Jersey at the Cooper University Hospital
Camden, New Jersey, 08103
Graham Hospital
Canton, Illinois, 61520
Memorial Hospital
Carthage, Illinois, 62321
St. Luke's Hospital
Cedar Rapids, Iowa, 52402
Cedar Rapids Oncology Associates
Cedar Rapids, Iowa, 52403
Mercy Cancer Center at Mercy Medical Center
Cedar Rapids, Iowa, 52403
Cancer Center of Kansas - Chanute
Chanute, Kansas, 66720
Roper St. Francis Healthcare - Roper Hospital
Charleston, South Carolina, 29401
West Virginia University - Robert C. Byrd Health Sciences Center - Charleston Division
Charleston, West Virginia, 25304
University of Chicago Cancer Research Center
Chicago, Illinois, 60637-1470
Louis A. Weiss Memorial Hospital
Chicago, Illinois, 60640
Adena Regional Medical Center
Chillicothe, Ohio, 54601
Ireland Cancer Center at University Hospitals of Cleveland and Case Western Reserve University
Cleveland, Ohio, 44106
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, 44195
Penrose Cancer Center at Penrose Hospital
Colorado Springs, Colorado, 80933
Missouri Cancer Associates
Columbia, Missouri, 65201
John B. Amos Community Cancer Center
Columbus, Georgia, 31902
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University
Columbus, Ohio, 43210
Riverside Methodist Hospital Cancer Care
Columbus, Ohio, 43214
CCOP - Columbus
Columbus, Ohio, 43215
Grant Riverside Cancer Services
Columbus, Ohio, 43215
Mount Carmel West Hospital
Columbus, Ohio, 43222
Doctors Hospital at Ohio Health
Columbus, Ohio, 43228
Batte Cancer Center at Northeast Medical Center
Concord, North Carolina, 28025
Mercy Hospital
Coon Rapids, Minnesota, 55433
Geisinger Medical Center
Danville, Pennsylvania, 17822-2001
Danville Regional Medical Center
Danville, Virginia, 24541
Genesis Regional Cancer Center at Genesis Medical Center
Davenport, Iowa, 52803
Genesis Medical Center - West Campus
Davenport, Iowa, 52804
Grandview Hospital
Dayton, Ohio, 45405
Good Samaritan Hospital
Dayton, Ohio, 45406
Miami Valley Hospital
Dayton, Ohio, 45409
Samaritan North Cancer Care Center
Dayton, Ohio, 45415
Veterans Affairs Medical Center - Dayton
Dayton, Ohio, 45428
CCOP - Dayton
Dayton, Ohio, 45429
Grady Memorial Hospital
Delaware, Ohio, 43015
Porter Adventist Hospital
Denver, Colorado, 80210
Presbyterian - St. Luke's Medical Center
Denver, Colorado, 80218
St. Joseph Hospital
Denver, Colorado, 80218
Rose Medical Center
Denver, Colorado, 80220
CCOP - Colorado Cancer Research Program, Incorporated
Denver, Colorado, 80224-2522
Mercy Capitol Hospital
Des Moines, Iowa, 50307
CCOP - Iowa Oncology Research Association
Des Moines, Iowa, 50309
John Stoddard Cancer Center at Iowa Methodist Medical Center
Des Moines, Iowa, 50309
Medical Oncology and Hematology Associates at John Stoddard Cancer Center
Des Moines, Iowa, 50309
Medical Oncology and Hematology Associates at Mercy Cancer Center
Des Moines, Iowa, 50314
Mercy Cancer Center at Mercy Medical Center - Des Moines
Des Moines, Iowa, 50314
John Stoddard Cancer Center at Iowa Lutheran Hospital
Des Moines, Iowa, 50316
Cancer Center of Kansas - Dodge City
Dodge City, Kansas, 67801
Wendt Regional Cancer Center at Finley Hospital
Dubuque, Iowa, 52001
Duke Comprehensive Cancer Center
Durham, North Carolina, 27710
Veterans Affairs Medical Center - East Orange
East Orange, New Jersey, 07018-1095
John Smith, Jr./Dalton McMichael Cancer Center at Morehead Memorial Hospital
Eden, North Carolina, 27288
Fairview Southdale Hospital
Edina, Minnesota, 55435
Cancer Center of Kansas, P.A. - El Dorado
El Dorado, Kansas, 67042
Elkhart General Hospital
Elkhart, Indiana, 46515
Union Hospital Cancer Center at Union Hospital
Elkton MD, Maryland, 21921
Swedish Medical Center
Englewood, Colorado, 80110
Eureka Hospital
Eureka, Illinois, 61530
Front Range Cancer Specialists
Fort Collins, Colorado, 80524
Poudre Valley Hospital
Fort Collins, Colorado, 80524
Michael & Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital
Fort Lauderdale, Florida, 33308
Mercy and Unity Cancer Center at Mercy and Unity Hospitals
Fridley, Minnesota, 55432
Galesburg Clinic
Galesburg, Illinois, 61401
Galesburg Cottage Hospital
Galesburg, Illinois, 61401
InterCommunity Cancer Center of Western Illinois
Galesburg, Illinois, 61401
Charles R. Wood Cancer Center at Glens Falls Hospital
Glens Falls, New York, 12801
Legacy Mount Hood Medical Center
Glesham, Oregon, 97030
Wayne Memorial Hospital, Incorporated
Goldsboro, North Carolina, 27534
Great Falls Clinic
Great Falls, Montana, 59405
Sletten Regional Cancer Institute
Great Falls, Montana, 59405
Moses Cone Regional Cancer Center at Wesley Long Community Hospital
Greensboro, North Carolina, 27401
Bon Secours St. Francis Health System
Greenville, South Carolina, 29601
Greenville Hospital System Cancer Center
Greenville, South Carolina, 29605
CCOP - Greenville
Greenville, South Carolina, 29615
CCOP - Northern New Jersey
Hackensack, New Jersey, 07601
Cancer Institute of New Jersey at Hamilton
Hamilton, New Jersey, 08690
Mason District Hospital
Havana, Illinois, 62644
St. Peter's Hospital
Helena, Montana, 59601
Penn State Cancer Institute at Milton S. Hershey Medical Center
Hershey, Pennsylvania, 17033-0850
Memorial Cancer Institute at Memorial Regional Hospital
Hollywood, Florida, 33021
Hopedale Medical Complex
Hopedale, Illinois, 61747
St. Mary's Medical Center
Huntington, West Virginia, 25702
Hutchinson Area Health Care
Hutchinson, Minnesota, 55350
Community Oncology Group - Independence
Independence, Ohio, 44131
Indiana University Cancer Center
Indianapolis, Indiana, 46202
William N. Wishard Memorial Hospital
Indianapolis, Indiana, 46202
Holden Comprehensive Cancer Center at University of Iowa
Iowa City, Iowa, 52242
Mayo Clinic - Jacksonville
Jacksonville, Florida, 32224-9980
Joliet Oncology Hematology Associates, Limited - West
Joliet, Illinois, 60435
Ella Milbank Foshay Cancer Center at Jupiter Medical Center
Jupiter, Florida, 33458
Bronson Methodist Hospital
Kalamazoo, Michigan, 49007
West Michigan Cancer Center
Kalamazoo, Michigan, 49007
Borgess Medical Center
Kalamazooaa, Michigan, 49001
Kalispell Regional Medical Center
Kalispell, Montana, 59901
Provena St. Mary's Wasser Regional Cancer Center - Kankakee
Kankakee, Illinois, 60901
CCOP - Kansas City
Kansas City, Missouri, 64131
Charles F. Kettering Memorial Hospital
Kettering, Ohio, 45429
Kewanee Hospital
Kewanee, Illinois, 61443
Cancer Center of Kansas - Kingman
Kingman, Kansas, 67068
Lenoir Memorial Cancer Center
Kinston, North Carolina, 28501
Cancer Treatment Center at Merle West Medical Center
Klamath Falls, Oregon, 97601
Gundersen Lutheran Cancer Center at Gundersen Lutheran Medical Center
La Crosse, Wisconsin, 54601
Center for Cancer Therapy at LaPorte Hospital and Health Services
La Porte, Indiana, 46350
Watson Clinic
Lakeland, Florida, 33805
Fairfield Medical Center
Lancaster, Ohio, 43130
University Medical Center of Southern Nevada
Las Vegas, Nevada, 89102
CCOP - Southern Nevada Cancer Research Foundation
Las Vegas, Nevada, 89106
Central Pennsylvania Hematology and Medical Oncology Associates, PC
Lemoyne, Pennsylvania, 17043
Beebe Medical Center
Lewes, Delaware, 19958
Central Maine Medical Center
Lewiston, Maine, 04240
Lewistown Hospital
Lewistown, Pennsylvania, 17044
Southwest Medical Center
Liberal, Kansas, 67901
Meeker County Memorial Hospital
Litchfield, Minnesota, 55355
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205
Sky Ridge Medical Center
Lone Tree, Colorado, 80124
Hope Cancer Care Center at Longmont United Hospital
Longmont, Colorado, 80502
McDonough District Hospital
Macomb, Illinois, 61455
UW Health Oncology
Madison, Wisconsin, 53715
University of Wisconsin Comprehensive Cancer Center
Madison, Wisconsin, 53792
St. John's Hospital
Maplewood, Minnesota, 55109
Strecker Cancer Center at Marietta Memorial Hospital
Marietta, Ohio, 45750
Fox Chase Virtua Health Cancer Program - Marlton
Marlton, New Jersey, 08053
Marshfield Clinic - Marshfield Center
Marshfield, Wisconsin, 54449
Cardinal Bernardin Cancer Center at Loyola University Medical Center
Maywood, Illinois, 60153
Lawrence Memorial Hospital of Medford
Medford, Massachusetts, 02155
Riddle Memorial Hospital
Media, Pennsylvania, 19063
CCOP - Mount Sinai Medical Center
Miami Beach, Florida, 33140
Saint Anthony Memorial Health Centers
Michigan City, Indiana, 46360
Middletown Regional Hospital
Middletown, Ohio, 45044
Eastern Montana Cancer Center
Miles City, Montana, 59301
Medical College of Wisconsin Cancer Center
Milwaukee, Wisconsin, 53226
Providence Milwaukie Hospital
Milwaukie, Oregon, 97222
Virginia Piper Cancer Institute at Abbott-Northwestern Hospital
Minneapolis, Minnesota, 55407
Hennepin County Medical Center - Minneapolis
Minneapolis, Minnesota, 55415
Veterans Affairs Medical Center - Minneapolis
Minneapolis, Minnesota, 55417
Community Medical Center
Missoula, Montana, 59801
Montana Cancer Center at St. Patrick Hospital and Health Sciences Center
Missoula, Montana, 59802
Mary Babb Randolph Cancer Center at West Virginia University Hospitals
Morgantown, West Virginia, 26506
Vanderbilt-Ingram Cancer Center at Vanderbilt Medical Center
Nashville, Tennessee, 37232
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School
New Brunswick, New Jersey, 08903
CCOP - Christiana Care Health Services
Newark, Delaware, 19718
Licking Memorial Cancer Care Program at Licking Memorial Hospital
Newark, Ohio, 43055
Cancer Center of Kansas - Newton
Newton, Kansas, 67114
BroMenn Regional Medical Center
Normal, Illinois, 61761
Community Cancer Center
Normal, Illinois, 61761
Oklahoma University Medical Center
Oklahoma City, Oklahoma, 73104
Community Hospital of Ottawa
Ottawa, Illinois, 61350
Oncology Hematology Associates of Central Illinois - Ottawa
Ottawa, Illinois, 61350
Cancer Center of Kansas, P.A. - Parsons
Parsons, Kansas, 67357
Cancer Treatment Center at Pekin Hospital
Pekin, Illinois, 61554
Methodist Medical Center of Illinois
Peoria, Illinois, 61603
Proctor Hospital
Peoria, Illinois, 61614
CCOP - Illinois Oncology Research Association
Peoria, Illinois, 61615
Oncology/Hematology Associates of Central Illinois, P.C.
Peoria, Illinois, 61615
OSF St. Francis Medical Center
Peoria, Illinois, 61637
Illinois Valley Community Hospital
Peru, Illinois, 61354
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104
Joan Karnell Cancer Center at Pennsylvania Hospital
Philadelphia, Pennsylvania, 19107
Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
Philadelphia, Pennsylvania, 19107
Hillman Cancer Center at University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania, 15213
Saint Joseph Regional Medical Center - Plymouth Campus
Plymouth, Indiana, 46544
Comprehensive Cancer Center at Legacy Good Samaritan Hospital & Medical Center
Portland, Oregon, 97210
Providence Cancer Center at Providence Portland Medical Center
Portland, Oregon, 97213
CCOP - Columbia River Oncology Program
Portland, Oregon, 97225
Providence St. Vincent Medical Center
Portland, Oregon, 97225
Institute of Oncology at Vilnius University
Portland, Oregon, 97227
Pottstown Memorial Regional Cancer Center
Pottstown, Pennsylvania, 19464
Pratt Cancer Center of Kansas
Pratt, Kansas, 67124
Perry Memorial Hospital
Princeton, Illinois, 61356
Rhode Island Hospital
Providence, Rhode Island, 02903
Miriam Hospital at Lifespan
Providence, Rhode Island, 02906
St. Mary-Corwin Regional Medical Center
Pueblo, Colorado, 81004
Annie Penn Cancer Center
Reidsville, North Carolina, 27320
Hubert H. Humphrey Cancer Center at North Memorial Medical Center
Robbinsdale, Minnesota, 55422
Mayo Clinic Cancer Center
Rochester, Minnesota, 55905
Lipson Cancer and Blood Center at Rochester General Hospital
Rochester, New York, 14621
James P. Wilmot Cancer Center at University of Rochester Medical Center
Rochester, New York, 14642
William Beaumont Hospital - Royal Oak Campus
Royal Oak, Michigan, 48073
Rutherford Hospital
Rutherfordton, North Carolina, 28139
CCOP - Metro-Minnesota
Saint Louis Park, Minnesota, 55416
Park Nicollet Clinic
Saint Louis Park, Minnesota, 55416
Cancer Care Center at Regions Hospital
Saint Paul, Minnesota, 55101
St. Joseph's Hospital
Saint Paul, Minnesota, 55102
United Hospital
Saint Paul, Minnesota, 55102
Cancer Center of Kansas - Salina
Salina, Kansas, 67042
Rebecca and John Moores UCSD Cancer Center
San Diego, California, 92103
Kaiser Permanente Medical Office -Vandever Medical Office
San Diego, California, 92120
Veterans Affairs Medical Center - San Diego
San Diego, California, 92161
UCSF Comprehensive Cancer Center
San Francisco, California, 94115
Veterans Affairs Medical Center - San Francisco
San Francisco, California, 94121
Curtis & Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center
Savannah, Georgia, 31403
Maine Center for Cancer Medicine and Blood Disorders - Scarborough
Scarborough, Maine, 04074
CCOP - Mayo Clinic Scottsdale Oncology Program
Scottsdale, Arizona, 85259
Saint Francis Cancer Center
Shakopee, Minnesota, 55379
Welch Cancer Center
Sheridan, Wyoming, 82801
Siouxland Regional Cancer Center
Sioux City, Iowa, 51101-1733
Siouxland Hematology-Oncology Associates
Sioux City, Iowa, 51101
Mercy Medical Center - Sioux City
Sioux City, Iowa, 51104
St. Luke's Regional Medical Center
Sioux City, Iowa, 51104
Sioux Valley Hospital and University of South Dakota Medical Center
Sioux Falls, South Dakota, 57104
Avera McKennan Hospital and University Health Center
Sioux Falls, South Dakota, 57105
Medical X-Ray Center
Sioux Falls, South Dakota, 57105
CCOP - Northern Indiana CR Consortium
South Bend, Indiana, 46601
Memorial Hospital of South Bend
South Bend, Indiana, 46601
Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
Spartanburg, South Carolina, 29303
CCOP - Upstate Carolina
Spartanburg, South Carolina, 29304
Providence Cancer Center at Sacred Heart Medical Center
Spokane, Washington, 99204
Providence Cancer Center at Holy Family Hospital
Spokane, Washington, 99207
St. Margaret's Hospital
Spring Valley, Illinois, 61362
Valley Cancer Center
Spring Valley, Illinois, 61362
Regional Cancer Center at Memorial Medical Center
Springfield, Illinois, 62781-0001
St. John's Regional Health Center
Springfield, Missouri, 65804
Hulston Cancer Center at Cox Medical Center South
Springfield, Missouri, 65807
Mercy Medical Center Oncology Unit
Springfield, Ohio, 45504
Community Hospital of Springfield and Clark County
Springfield, Ohio, 45505
St. Anthony's Cancer Center
St Louis, Missouri, 63128
Geisinger Medical Group
State College, Pennsylvania, 16801
Mount Nittany Medical Center
State College, Pennsylvania, 16803
Long Island Cancer Center at Stony Brook University Hospital
Stony Brook, New York, 11794
CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C.
Syracuse, New York, 13057
Veterans Affairs Medical Center - Syracuse
Syracuse, New York, 13210
Community General Hospital of Greater Syracuse
Syracuse, New York, 13215
North Suburban Medical Center
Thorton, Colorado, 80229
UVMC Cancer Care Center at Upper Valley Medical Center
Troy, Ohio, 45373
Legacy Meridian Park Hospital
Tualatin, Oregon, 97062
Carle Cancer Center at Carle Foundation Hospital
Urbana, Illinois, 61801
CCOP - Carle Cancer Center
Urbana, Illinois, 61801
Cancer Center at Southwest Washington Medical Center
Vancouver, Washington, 98668
Fox Chase Virtua Health Cancer Program at Virtua West Jersey
Voorhees Township, New Jersey, 08043
Ridgeview Medical Center
Waconia, Minnesota, 55387
St. Joseph Health Care Center
Warren, Ohio, 44484
Lombardi Cancer Center at Georgetown University Medical Center
Washington D.C., District of Columbia, 20007
Walter Reed Army Medical Center
Washington D.C., District of Columbia, 20307
University of Wisconsin Cancer Center at Aspirus Wausau Hospital
Wausau, Wisconsin, 54401
Cancer Center of Kansas - Wellington
Wellington, Kansas, 67152
Medical Oncology and Hematology Associates - West Des Moines
West Des Moines, Iowa, 50266
Mount Carmel Cancer Services at Mount Carmel St. Ann's Hospital
Westerville, Ohio, 43081
Associates in Womens Health
Wichita, Kansas, 67203
Cancer Center of Kansas, P.A.
Wichita, Kansas, 67208
Cancer Center of Kansas, P.A. - Wichita
Wichita, Kansas, 67214
CCOP - Wichita
Wichita, Kansas, 67214
Via Christi Cancer Center at Via Christi Regional Medical Center
Wichita, Kansas, 67214
Geisinger Wyoming Valley Medical Center
Wilkes-Barre, Pennsylvania, 18711
St. Francis Hospital
Wilmington, Delaware, 19805
Wilson Medical Center
Wilson, North Carolina, 27893
Cancer Center of Kansas - Winfield
Winfield, Kansas, 67156
Comprehensive Cancer Center at Wake Forest University
Winston-Salem, North Carolina, 27157
Woodwinds Hospital
Woodbury, Minnesota, 55125
Cleveland Clinic - Wooster
Wooster, Ohio, 44691
Ruth G. McMillan Cancer Center at Greene Memorial Hospital
Xenia, Ohio, 45385
St. Elizabeth Cancer Center at St. Elizabeth Health Center - Youngstown
Youngstown, Ohio, 44510
Genesis - Good Samaritan Hospital
Zanesville, Ohio, 43701
About this study
Official title: Phase III Study Comparing Sequential Chemotherapy (AG-ITP) To Cisplatin And Gemcitabine As Adjuvant Treatment After Cystectomy For Transitional Cell Carcinoma Of The Bladder
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Randomized phase III trial to compare different combination chemotherapy regimens in treating patients who have advanced bladder cancer.
Read the detailed description
OBJECTIVES:
Primary
- Compare the survival of patients with completely resected locally advanced transitional cell carcinoma of the bladder treated with adjuvant doxorubicin and gemcitabine followed by paclitaxel and cisplatin vs adjuvant cisplatin and gemcitabine.
Secondary
- Compare the toxicity profiles of these regimens in these patients.
OUTLINE: This is a randomized study. Patients are stratified according to primary tumor status (<T4 vs T4), number of positive lymph nodes (0 or unknown vs 1-5 vs >5), and number of dissected nodes (0-10 or unknown vs > 10). Patients are randomized to one of two treatment arms.
- Arm I: Patients receive adjuvant gemcitabine IV over 30 minutes on days 1, 8, and 15 and cisplatin IV over 30-60 minutes on day 1. Treatment repeats every 4 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
- Arm II: Patients receive adjuvant doxorubicin IV over 45 minutes followed by gemcitabine IV over 2 hours on day 1. Patients also receive filgrastim (G-CSF) subcutaneously (SC) daily on days 3-10. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Beginning 14 days after the completion of doxorubicin and gemcitabine, patients receive paclitaxel IV over 3 hours and cisplatin IV over 20-30 minutes on day 1. Patients also receive G-CSF SC daily on days 3-10 or 4-11. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 18 months, every 6 months for 18 months, and then annually thereafter.
- Conditions
- Bladder Cancer
- Being tested
- filgrastim, cisplatin, doxorubicin hydrochloride, gemcitabine hydrochloride
- Keywords
- stage III bladder cancer, stage IV bladder cancer, transitional cell carcinoma of the bladder
- Medical subject headings
- Urinary Bladder Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
filgrastimBiological
6 mg sub Q
cisplatinDrug
60 mg/sq m IV
50 mg/ sq m IV
1000 mg/ sq m IV for Gem + cis arm and 2000 mg/sq m IV for gem + dox + peg arm
| Study group | Role | What they receive |
|---|---|---|
| Gemcitabine + cisplatin | Active comparator | Not described Receives: Drug: cisplatin; Drug: gemcitabine hydrochloride |
| Gemcitabine + Doxorubicin + Pegfilgrastim | Active comparator | Not described Receives: Biological: filgrastim; Drug: doxorubicin hydrochloride; Drug: gemcitabine hydrochloride |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall survival
Measured: 4 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jun 2003 (estimated)
- Study startMar 2004
- Primary completionJul 2005
- Study completionApr 2009
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Bladder CancerStudies of the same condition, open and under way.
- More trials run by Alliance for Clinical Trials in OncologyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 42 participants (actual)
Sponsor and investigators
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Dean Bajorin, MD, Study chair, Memorial Sloan Kettering Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00014534
- Sponsor's protocol ID
- CALGB-90104
- Other IDs
- P30CA008748, CALGB-90104, MSKCC-00138, NCI-G01-1935, CDR0000068554
- Status last verified
- Jul 2016
- First submitted
- 10 Apr 2001
- Last updated
- 14 Jul 2016
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 14 Jul 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Phase III Study Comparing Sequential Chemotherapy (AG-ITP) To Cisplatin And Gemcitabine As Adjuvant Treatment After Cystectomy For Transitional Cell Carcinoma Of The Bladder
- ClinicalTrials.gov ID
- NCT00014534
- Acronym / sponsor ID
- CALGB-90104
- Conditions
- Bladder Cancer
- Keywords
- stage III bladder cancer, stage IV bladder cancer, transitional cell carcinoma of the bladder
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 42 participants (actual)
- Lead sponsor
- Alliance for Clinical Trials in OncologyUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Study start
- Mar 2004
- Primary completion
- Jul 2005 (actual)
- Study completion
- Apr 2009 (actual)
- First posted
- 10 Jun 2003 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Randomized phase III trial to compare different combination chemotherapy regimens in treating patients who have advanced bladder cancer.
Detailed description
OBJECTIVES:
Primary
- Compare the survival of patients with completely resected locally advanced transitional cell carcinoma of the bladder treated with adjuvant doxorubicin and gemcitabine followed by paclitaxel and cisplatin vs adjuvant cisplatin and gemcitabine.
Secondary
- Compare the toxicity profiles of these regimens in these patients.
OUTLINE: This is a randomized study. Patients are stratified according to primary tumor status (<T4 vs T4), number of positive lymph nodes (0 or unknown vs 1-5 vs >5), and number of dissected nodes (0-10 or unknown vs > 10). Patients are randomized to one of two treatment arms.
- Arm I: Patients receive adjuvant gemcitabine IV over 30 minutes on days 1, 8, and 15 and cisplatin IV over 30-60 minutes on day 1. Treatment repeats every 4 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
- Arm II: Patients receive adjuvant doxorubicin IV over 45 minutes followed by gemcitabine IV over 2 hours on day 1. Patients also receive filgrastim (G-CSF) subcutaneously (SC) daily on days 3-10. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Beginning 14 days after the completion of doxorubicin and gemcitabine, patients receive paclitaxel IV over 3 hours and cisplatin IV over 20-30 minutes on day 1. Patients also receive G-CSF SC daily on days 3-10 or 4-11. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 18 months, every 6 months for 18 months, and then annually thereafter.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Gemcitabine + cisplatin | Active comparator | Drug: cisplatin, Drug: gemcitabine hydrochloride |
| Gemcitabine + Doxorubicin + Pegfilgrastim | Active comparator | Biological: filgrastim, Drug: doxorubicin hydrochloride, Drug: gemcitabine hydrochloride |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| filgrastim6 mg sub Q | Biological | Gemcitabine + Doxorubicin + Pegfilgrastim |
| cisplatin60 mg/sq m IV | Drug | Gemcitabine + cisplatin |
| doxorubicin hydrochloride50 mg/ sq m IV | Drug | Gemcitabine + Doxorubicin + Pegfilgrastim |
| gemcitabine hydrochloride1000 mg/ sq m IV for Gem + cis arm and 2000 mg/sq m IV for gem + dox + peg arm | Drug | Gemcitabine + Doxorubicin + Pegfilgrastim, Gemcitabine + cisplatin |
Primary outcome
Overall survival
Time frame: 4 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Jul 2016.
Related trials for Bladder Cancer
RecruitingPhase 2/3
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma
RecruitingPhase 3
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055)
Bladder Cancer
Active, not recruitingPhase 2/3
A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)
Biliary Tract Cancer, Cholangiocarcinoma
Recruiting
Effect of Cyclic Sighing Breathing Exercise on CRBD, Pain, and Sleep Quality in Patients Undergoing TUR
Transurethral Resection of Bladder Tumor, Transurethral Resection of the Prostate (TURP)
Recruiting
The Vanguard Study: Testing a New Way to Screen for Cancer
Bladder Carcinoma, Breast Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Dean Bajorin, MD study chair
Memorial Sloan Kettering Cancer Center
285 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing filgrastim, cisplatin and doxorubicin hydrochloride in people with Bladder Cancer, run by Alliance for Clinical Trials in Oncology at 285 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Jul 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 285 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall survival (time frame: 4 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jul 2016.